Binay Shah, President of the Binaytara, shared on LinkedIn:
“Over 90% of cervical cancer deaths happen in LMICs. Often the cause is simply that screening never reaches the woman.
Our Binaytara Cancer Research Institute team just published a scoping review on whether newer HPV tests can help close that gap. The review looked at isothermal assays alongside careHPV, using studies from 2020 to 2025.
What they found:
- Isothermal tests detected 94.7-100% of CIN3+ lesions
- Self-sampling and dry-swab transport make testing easier where labs are far away
- Screen-and-treat cuts loss to follow-up, and phone-based linkage helps further
- Specificity varies widely by setting, and cost and cultural acceptance are still real barriers
This matters to us because it’s the problem our teams work on in Madhesh Province, Nepal.
Better tests are part of the answer. Getting women to accept them, and following up afterward, is the rest.”
Title: Advances in isothermal nucleic acid amplification-based HPV assays for cervical cancer screening in low- and middle-income countries: A scoping review
Authors: Mou In, Suchit Shashikumar, Aman Kumar Shah, Amit Chaudhary, Prity Lata Chakraborty, Angelina Yang, Angira Shah
You can also read:
David Antonio Pérez: New Study on Cervical Cancer Care In Latin America
